Technologies

This innovative technology involves the use of a high-affinity, highly specific antibody that targets extracellular domains of connexin hemichannels (Cx26, Cx30, and Cx32). The antibody has been designed to reduce or inhibit the growth of brain tumors, particularly glioblastoma (GBM), and to alleviate the associated epilepsy. By blocking connexin hemichannels, the antibody interferes with pathological ATP release and other signaling mechanisms that contribute to tumor progression and neural hyperexcitability.

Nowadays, to properly design and develop advanced materials capable to preserve for long times their performance under aggressive environments such as power generation plants, renewables, nuclear reactors and electronics of new generation, transport on ground and on space, aeronautics, catalysis, biomedical implants, the optimization of metallurgical processes involved is crucial.

Uniform coverage with porous layers over extended surfaces is beneficial for many purposes. Depending on the nature/composition, thickness and interfaces of the layer, this kind of special coverage can assure pivotal properties such as transparency, bendability, high surface reactivity, intermixing capability. In the long list of desired porous materials, transparent oxides find application in the fields of Photovoltaics, Sensing, Photocatalysis, Water Purification and Splitting, Lithium Batteries and many more.

Cheese making is an ancient practice to preserve  perishable food such as milk for a long time. The first phase of cheese making involves the addition of rennet of animal origin, which contains the enzymes necessary for the hydrolysis and coagulation of milk caseins, and for cheese ripening (mainly lipase/esterase).

We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.